Employees: 552
Size Ocumension Therapeutics (1477.HK) is a Hong Kong Industrials company (Miscellaneous Commercial Services) with a market value of $501M, the 743rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.86 on 18 Nov 2026.
Performance Over six months the shares fell 24.1%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 77.5% over the last twelve months (peer median +10.1%); the operating margin is -13.5% (peer median 11.3%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 3.2× (7th most expensive of 20).
Capital Return on invested capital runs 12.7 points below its cost of capital (9.8% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.04B | HK$872M | HK$452M | HK$272M | HK$185M |
| Revenue growth | — | +93% | +66% | +47% | — |
| Gross profit | HK$482M | HK$382M | HK$233M | HK$150M | HK$116M |
| EBITDA | HK$28.7M | -HK$17.9M | -HK$236M | -HK$381M | -HK$483M |
| Net income | -HK$142M | -HK$172M | -HK$291M | -HK$420M | -HK$468M |
| Free cash flow | -HK$55.4M | -HK$138M | -HK$219M | -HK$259M | -HK$336M |
| Capital expenditure | HK$309M | HK$275M | HK$250M | HK$400M | HK$360M |
| Total debt | n/a | HK$209M | HK$27.4M | HK$152M | HK$33.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1477.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | -7.5% | 5th highest of 21 |
| 6-month return | -24.1% | -6.6% | 9th lowest of 21 |
| Distance from 52-week high | -45.6% | -34.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +77.5% | +10.1% | 2nd highest of 21 |
| Operating margin | -13.5% | 11.3% | 3rd lowest of 21 |
| EV / Sales | 3.5× | 3.2× | 7th most expensive of 20 |
| ROIC minus cost of capital | -12.7 pp | +3.8 pp | 3rd lowest of 19 |
| Net debt / EBITDA | -9.5× | -1.9× | 2nd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ocumension Therapeutics 1477.HK | Hong Kong | $501M | -24% | +78% | -13% | 3.5× | n/a | n/a |
| Baotou INST Magnetic New Materials 301622.SZ | China | $501M | -50% | +3% | -1% | 2.4× | n/a | n/a |
| C.E. Info Systems MAPMYINDIA.NS | India | $499M | -12% | +3% | 31% | 8.3× | 31.7% | +25.5% |
| BTS BTS-B.ST | Sweden | $499M | +34% | 0% | 9% | 1.9× | 7.6% | +13.0% |
| Winstek Semiconductor 3265.TWO | Taiwan | $499M | -27% | +15% | 20% | 3.3× | n/a | n/a |
| Mitsubishi Research Institute 3636.T | Japan | $505M | +11% | +4% | 7% | 0.5× | -8.6% | +4.1% |
| LINE Pay Taiwan 7722.TW | Taiwan | $496M | +1% | +15% | 6% | n/a | n/a | n/a |
| Qingdao Paguld Intelligent Manufacturing 301456.SZ | China | $494M | -32% | +29% | 13% | 3.2× | n/a | n/a |
| MHA MHA.L | United Kingdom | $493M | -6% | +12% | 15% | 1.5× | -14.9% | +30.6% |
| Shenzhen Manst Technology 301325.SZ | China | $493M | -45% | -52% | -44% | 4.8× | n/a | n/a |
| Zhejiang Zoenn Design 300901.SZ | China | $512M | -24% | +53% | 10% | 7.0× | n/a | n/a |
| Xuanzhu Biopharmaceutical 2575.HK | Hong Kong | $514M | -60% | +237% | -187% | 29.0× | n/a | n/a |
| Hunan SUND Technological 301548.SZ | China | $518M | -51% | +23% | 21% | 3.5× | 16.7% | +13.8% |
| Academy of Environmental Planning & Design Co., Ltd. Nanjing University 300864.SZ | China | $519M | -7% | +5% | 18% | 3.3× | 8.9% | +10.6% |
| eGuarantee 8771.T | Japan | $482M | +2% | +3% | 47% | 5.7× | -7.9% | +8.3% |
| Prestige International 4290.T | Japan | $521M | -2% | +10% | 13% | 0.9× | -12.4% | +11.8% |
| GPI GPI.MI | Italy | $478M | +2% | +2% | 6% | 1.6× | n/a | n/a |
| Jiangsu Chuanzhiboke Education Technology 003032.SZ | China | $525M | +27% | +63% | -7% | 5.8× | n/a | n/a |
| Pony Testing 300887.SZ | China | $477M | -38% | -2% | -12% | 1.9× | n/a | n/a |
| Premium 7199.T | Japan | $475M | -3% | +21% | 20% | 0.9× | -18.5% | +20.6% |
| Gabia 079940.KS | South Korea | $474M | +43% | +10% | 15% | 1.7× | -7.6% | +14.7% |